Keros Therapeutics Inc. Stock News

Data is promising for KROS' KER-050 compound; investors are rewarding the company on its novel hypotheses. We performed a deep dive on its most recent readouts on KER-050.

LEXINGTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci

Keros Therapeutics, Inc. (KROS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

LEXINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci

Keros Therapeutics, Inc. (KROS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

A sympathetic reaction to a competitor's drug helped push the clinical-stage pharmaceutical company's shares higher.

LEXINGTON, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021.

Related Stocks: ATRC , KROS , BCYC , CDXS , PFE , MEIP , BLU , FNA , NGM , MRTX , CRNX , PLRX , ALDX , XBI , YMAB , STIM , APTO , WW ,

Keros Therapeutics Inc (KROS) shares closed this week 21.0% higher than it did at the end of last week. The stock is currently down 10.2% year-to-date, down 22.3% over the past 12 months, and up 161.7% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $55.79 and as low as $42.32 this week.Trading volume this week was 0.7% higher than the 10-day average and 15.1% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -3.3% The company's stock price performance over the past 12 months beats the peer average by -34.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

LEXINGTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D. will present at the 11 th Annual SVB Leerink Global Healthcare Conference on Friday, February 18th at 9:20 am ET.

LEXINGTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci

Keros Therapeutics (KROS) has appointed Christopher Rovaldi as Keros'' Chief Operating Officer, effective as of February 1, 2022.Mr

Related Stocks: KROS , CRNX , OPTN , SMLR , FOLD , MRUS , DTIL , AADI , NCNA , MGNX , SIOX , APTO , AVEO , EPIX , MCRB , CMLF , LUMO , KZR , CRDF ,

Keros Therapeutics, Inc. (NASDAQ:KROS) insider Jennifer Lachey sold 735 shares of the firms stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $50.00, for a total transaction of $36,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this []

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) gapped down before the market opened on Tuesday . The stock had previously closed at $53.82, but opened at $47.00. Keros Therapeutics shares last traded at $47.02, with a volume of 303 shares trading hands. Separately, Zacks Investment Research upgraded Keros Therapeutics from a “sell” rating to a “hold” […]